Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pozzuoli – page 70

1 231 clinical trials in Pozzuoli, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pozzuoli at a glance
1 231
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 231 trials in Pozzuoli

Open in trial search

Transitional cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin Hydrochloride
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hepatocellular carcinoma

Not recruiting

Study Comparing Toripalimab and Lenvatinib with Placebo and Lenvatinib for First-Line Treatment in Patients with Advanced Liver Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Fabry's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pegunigalsidase Alfa
  • Sponsor:Chiesi Farmaceutici S.p.A.

Colorectal cancer metastatic

Not recruiting

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Fondazione GONO G.I.

Non-small cell lung cancer

Not recruiting

Study of Chemotherapy with Osimertinib in Non-Small Cell Lung Cancer Patients Who Have Progressed After Initial Osimertinib Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Pozzuoli

What the registry says about research in the country

01 Neoplasms

Clinical trial activity in Località la Schiana, Pozzuoli is strongly focused on cancer research, with studies examining how to improve treatment options for several advanced solid tumors. The main goal is to test new therapeutic strategies and refine existing combinations for better disease control and patient outcomes.

  • Colorectal cancer, including metastatic and unresectable forms
  • Metastatic castration-resistant prostate cancer
  • Metastatic renal cell carcinoma
  • Breast cancer with hormone receptor-positive, HER2-negative disease

These studies are exploring more effective ways to slow progression, overcome treatment resistance, and improve survival in patients with advanced neoplasms.

02 Digestive System Diseases

Several trials in this site concentrate on digestive system cancers, especially advanced colorectal cancer. Research is centered on evaluating treatment effectiveness and finding better options for patients whose disease has already progressed or carries specific genetic changes.

  • RAS-mutant metastatic colorectal cancer
  • RAS/BRAF wild-type metastatic colorectal cancer
  • Unresectable left-sided metastatic colorectal cancer
  • Patients with metastatic colorectal cancer

Across these studies, the focus is on improving tumor response, extending disease control, and identifying which patients may benefit most from targeted treatment approaches.

03 Analytical, Diagnostic and Therapeutic Techniques and Equipment

This research landscape also includes therapeutic techniques aimed at improving how treatments are delivered and how response is monitored. The trials are not only testing active therapies, but also looking for better ways to understand resistance, safety, and treatment benefit in real-world patients.

  • Biomarker research for resistance and treatment monitoring
  • Safety and tolerability comparisons between treatment strategies
  • Quality of life assessments during therapy
  • Therapy optimization in advanced cancer care

In this part of the research portfolio, investigators in Pozzuoli are helping shape more precise and patient-centered cancer care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.